Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shalini Varma

Psychiatry Kenosha, WI Medical Doctor

NPI 1760648406 CMS profile 670078

7400 60Th Ave Ste B, Kenosha, WI 53142

Open in the dashboard

General payments

$11,586

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shalini Varma of Kenosha, WI is reported in the CMS Open Payments database as having received $11,586 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,338 55
2024 General $1,792 64
2023 General $2,180 92
2022 General $1,563 67
2021 General $2,052 81
2020 General $1,849 84
2019 General $811 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shalini Varma
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Shalini Varma were reported at $1,338. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Shalini Varma Psychiatry median Middle half National median
2019 $811 $184 $59–$605 $163
2020 $1,849 $119 $36–$372 $114
2021 $2,052 $143 $43–$576 $132
2022 $1,563 $153 $50–$590 $149
2023 $2,180 $170 $56–$651 $160
2024 $1,792 $179 $57–$673 $164
2025 $1,338 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $2,329 85 payments
  2. Vanda Pharmaceuticals Inc. $1,552 63 payments
  3. ITI, Inc. $1,548 55 payments
  4. Lundbeck LLC $1,335 65 payments
  5. Neurocrine Biosciences, Inc. $993 36 payments
  6. Otsuka America Pharmaceutical, Inc. $571 30 payments
  7. Axsome Therapeutics, Inc. $530 20 payments
  8. Avanir Pharmaceuticals, Inc. $428 12 payments
  9. Ironshore Pharmaceuticals Inc. $326 20 payments
  10. Allergan Inc. $260 16 payments
  11. Other $1,714 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,574 474 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. HETLIOZ $1,498 61 payments
  2. VYVANSE $1,365 50 payments
  3. CAPLYTA Psychiatry $1,116 37 payments
  4. ABILIFY MAINTENA $1,065 50 payments
  5. INGREZZA $993 36 payments
  6. TRINTELLIX $963 35 payments
  7. FANAPT $913 37 payments
  8. REXULTI $512 27 payments
  9. Auvelity $505 19 payments
  10. CAPLYTA Psychiatry $432 18 payments
  11. Other $3,664 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

246

Median for Psychiatry: 574

Drug cost

$2,336

Median for Psychiatry: $27,624

Branded share of claims

16.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 13 $877
Bupropion Xl Bupropion Hcl Brand 12 $368
Mirtazapine Generic 31 $211
Duloxetine Hcl Generic 24 $197
Trazodone Hcl Generic 23 $172
Venlafaxine Hcl Er Venlafaxine Hcl Brand 29 $141
Sertraline Hcl Generic 45 $116
Fluoxetine Hcl Generic 16 $115
Buspirone Hcl Generic 23 $80
Lamotrigine Generic 19 $53

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $876
$876 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $555
$555 — —
Auvelity
  • Axsome Therapeutics, Inc. $93
$93 — —
VRAYLAR
  • AbbVie, Inc. $89
$89 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record